Structure Therapeutics Inc. American Insider Trading Activity

Accepted by SEC EDGAR 07/03/2025 - 05:15 PM EDT Learn about SEC filing dates

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Coll Crespo Blas

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	7,992	$0.00	$0.00
Exercise Price or Tax Liability	Ordinary Shares	1,434	$6.8366	$10K
Grant/Award	American Depositary Shares	429	$0.00	$0.00
Exercise Price or Tax Liability	Ordinary Shares	1,233	$7.9166	$10K
Holding	American Depositary Shares	--	--	--

Holdings After Transaction: American Depositary Shares — 1,157 contracts (Direct); Ordinary Shares — 224,913 shares (Direct); American Depositary Shares — 3,000 contracts (Indirect, By spouse)

Holdings Before and After: American Depositary Shares, 728 to 1,157 contracts (Direct); Ordinary Shares, 219,588 to 224,913 shares (Direct)

Footnotes (5)

1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
2. F2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.
3. F3. On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date.
4. F4. Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date.
5. F5. Voluntary reporting of the acquisition of 429 ADSs by the Reporting Person on May 21, 2025 pursuant to the Issuer's Employee Share Purchase Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coll Crespo Blas

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/01/2025		F		1,233(2)	D	$7.9166	218,355	D
Ordinary Shares(1)	07/01/2025		A(3)		7,992	A	$0	226,347	D
Ordinary Shares(1)	07/01/2025		F		1,434(2)	D	$6.8366	224,913	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	(4)	05/21/2025		A(5)	V	429		(4)	(4)	Ordinary Shares(1)	1,287	$0	1,157	D
American Depositary Shares	(4)							(4)	(4)	Ordinary Shares(1)	3,000		1,000	I	By spouse

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

3. On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date.

4. Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date.

5. Voluntary reporting of the acquisition of 429 ADSs by the Reporting Person on May 21, 2025 pursuant to the Issuer's Employee Share Purchase Plan.

	/s/ Jun Yoon, Attorney-in-Fact	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.